Bill Lin

Dr. Bill Lin is the Chief Operating Officer at CryBioMedicines, a biotechnology company focused on developing anti-parasitic medicine for the treatment of intestinal worms using naturally occurring proteins. In that role, he is responsible for both operations and business development.

Prior to this assignment, Bill was with Johnson & Johnson for 24 years. Originally trained in molecular biology, Bill held leadership positions in business development in the medical devices and pharmaceutical sectors in technical and operational capacities. The business experience positioned him to transition to J&J’s Social Responsibility group in 2005, where he led global health and development portfolios of programs in disaster relief, product donations, and children’s health. He implemented the company’s largest medicine donation initiative to deworm and prevent parasitic infection in children. The program has donated more than 1 billion treatments of deworming medicines to the global initiative and made a significant contribution to reaching the WHO target to treat more than 75% of the at-risk children in many of the endemic countries globally.

Bill remains committed to the health and wellbeing of the underserved. In addition to leading the operations within CryBioMedicines, whose mission is to control and eliminate intestinal worms as a public health problem, he also serves on boards and committees of academic institutions and non-profit organizations whose missions are to advance the public health agenda.